Ticagrelor or Prasugrel in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous...

Area of Science:

• Cardiology
• Interventional Cardiology
• Pharmacology

Background:

• Limited data exist on ticagrelor vs. prasugrel in ST-segment-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI).
• This study provides a head-to-head comparison of these antiplatelet agents in a specific high-risk patient population.

Purpose of the Study:

• To compare the efficacy and safety of ticagrelor versus prasugrel in STEMI patients undergoing primary PCI.
• To assess the rates of major adverse cardiovascular events and bleeding between the two treatment groups.

Main Methods:

• A subgroup analysis of 1653 STEMI patients from the ISAR REACT-5 trial was conducted.
• Patients were randomized to receive either ticagrelor or prasugrel.
• Primary endpoint: death, myocardial infarction, or stroke at 1 year. Secondary endpoint: Bleeding Academic Research Consortium (BARC) type 3-5 bleeding at 1 year.

Main Results:

• No significant difference was observed in the primary endpoint (composite of death, MI, or stroke) between ticagrelor and prasugrel groups (10.1% vs. 7.9%, P=0.10).
• Ticagrelor was associated with a significantly higher incidence of myocardial infarction compared to prasugrel (5.3% vs. 2.8%, P=0.010).
• Rates of death, stroke, stent thrombosis, and BARC type 3-5 bleeding did not differ significantly between the groups.

Conclusions:

• In STEMI patients undergoing primary PCI, prasugrel and ticagrelor demonstrated comparable overall efficacy regarding the primary composite endpoint.
• Ticagrelor use was associated with an increased risk of recurrent myocardial infarction.
• The choice between ticagrelor and prasugrel in this setting warrants careful consideration of individual patient risk factors.